文献速递妇科肿瘤

氟唑帕利联合或不联合阿帕替尼一线维持治疗晚期卵巢癌:FZOCUS-1 III期随机双盲安慰剂对照试验

Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
PubMed 文献 · CA Cancer J Clin · 2026-01-01

最终分析显示,联合组和单药组中位BIRC评估PFS分别为26.9个月和29.9个月,均优于安慰剂组的11.1个月;在HRD患者中联合治疗未较单药延长PFS。

要点

  • 氟唑帕利联合或不联合阿帕替尼一线维持均较安慰剂显著改善晚期卵巢癌PFS。
  • HRD患者中联合阿帕替尼未较氟唑帕利单药延长PFS(34.1 vs 35.8个月)。
  • HRP患者中联合治疗PFS有获益趋势(16.6 vs 11.0个月;HR 0.73)。

核心结论

  • 氟唑帕利单药及联合阿帕替尼一线维持治疗均较安慰剂改善新诊断晚期卵巢癌患者的PFS。
  • 在HRD患者中,氟唑帕利联合阿帕替尼未较氟唑帕利单药延长PFS。
  • 在HRP患者中,联合治疗较单药显示出PFS获益趋势。

研究设计与样本

  • 多中心、随机、双盲、安慰剂对照III期试验(FZOCUS-1)。
  • 纳入新诊断晚期卵巢癌且一线铂类化疗后缓解的患者,按2:2:1随机分配。
  • 主要终点为BIRC评估的PFS。

主要发现

  • 最终分析(2024年11月1日;385例BIRC评估PFS事件;中位随访40个月)时,联合组中位BIRC评估PFS为26.9个月,安慰剂组为11.1个月(HR 0.57;95%CI 0.44-0.75;单侧p<.0001)。
  • 氟唑帕利单药组中位BIRC评估PFS为29.9个月,安慰剂组为11.1个月(HR 0.58;95%CI 0.44-0.75;单侧p<.0001)。
  • 无论胚系BRCA1/2突变状态如何,均观察到PFS获益。
  • HRD患者中,联合组与单药组PFS相似(34.1 vs 35.8个月)。
  • HRP患者中,联合组PFS有获益趋势(16.6 vs 11.0个月;HR 0.73;95%CI 0.45-1.19)。

关键数值与推荐

  • 联合组给药方案:氟唑帕利100 mg每日两次联合阿帕替尼375 mg每日一次。
  • 单药组给药方案:氟唑帕利150 mg每日两次联合安慰剂。
  • 对照组:双安慰剂。

临床怎么用

  • 氟唑帕利单药或联合阿帕替尼可作为新诊断晚期卵巢癌一线铂类化疗缓解后的维持治疗选择。
  • HRD患者选择维持方案时,联合阿帕替尼未显示较氟唑帕利单药额外PFS获益。
  • HRP患者可考虑氟唑帕利联合阿帕替尼以获取PFS获益趋势。

局限性

  • 总生存数据尚不成熟。
  • HRP亚组联合治疗对比单药的PFS获益趋势未达统计学显著(95%CI 0.45-1.19)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis) and bevacizumab were approved as first-line maintenance for advanced ovarian cancer (OC), evidence comparing this combination with PARPi monotherapy, especially in BRCA-mutated/homologous recombination-deficient (HRD) patients, is lacking. This study compared combined fuzuloparib (a PARPi) plus apatinib (a vascular endothelial growth factor receptor-2 inhibitor) with either fuzuloparib or placebo as first-line maintenance in patients with advanced OC. Patients who had newly diagnosed, advanced OC and responded to first-line, platinum-based chemotherapy were randomized 2:2:1 to receive combined fuzuloparib (100 mg twice daily) plus apatinib (375 mg daily), fuzuloparib (150 mg twice daily) plus placebo, or double-placebo treatment. The primary end point was blinded independent review committee (BIRC)-assessed progression-free survival (PFS). Six hundred seventy-four patients were randomized to receive fuzuloparib plus apatinib (n = 269), fuzuloparib (n = 269), or placebo (n = 136). At the final analysis (November 1, 2024; 385 BIRC-assessed PFS events; median follow-up, 40 months), the median BIRC-assessed PFS was 26.9 months with the combination versus placebo (hazard ratio [HR], 0.57; 95% confidence interval [CI], 0.44-0.75; one-sided p < .0001) and 29.9 months with fuzuloparib monotherapy versus placebo (HR, 0.58; 95% CI, 0.44-0.75; one-sided p < .0001) compared with 11.1 months with placebo. A PFS benefit was observed regardless of germline BRCA1/2 mutation status. In homologous recombination-deficient patients (including those with BRCA1/2 mutations), combined fuzuloparib and apatinib produced a PFS similar to that of fuzuloparib (34.1 vs. 35.8 months, respectively); in homologous recombination-proficient patients, PFS had a trend favoring the combination (16.6 vs. 11.0 months; HR, 0.73; 95% CI, 0.45-1.19). Both treatments were well tolerated. Overall survival was immature. Both fuzuloparib and combination therapy improved PFS compared with placebo as maintenance therapy for patients who had newly diagnosed, advanced OC. Adding apatinib to fuzuloparib did not prolong PFS among homologous recombination-deficient patients. There was a PFS benefit trend among homologous recombination-proficient patients who received combination therapy compared with those who received monotherapy.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Wu L, Wang J, Li Q, et al. Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial. CA Cancer J Clin. 2026. PMID: 41287969. doi:10.3322/caac.70042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。